CTLA4 and neoplasm: Anti-tumor immunity may be augmented by targeting negative regulators of T cell co-stimulation as evidenced by the development of anti-CTLA4 and anti-PD1 therapeutics, and may be extended to targeting Tregs and MDSCs [41].